

## QuikFlo provides update

Calgary, Alberta, May 24, 2016 – QuikFlo Health Inc. ("QuikFlo" or the "Company") (TSXV:QF)(FRANKFURT:1QF) announced that further to its press release of March 21, 2016 that the Company has amended the terms of its current private placement to \$0.10 per Unit, each units consisting of one common share and one 18 month common share warrant exercisable at \$0.20.

The Company would also like to announce the recent resignation of Dr. Bijoy Menon. The Company wishes to thank Dr. Menon for his contribution to the Company.

The Company continues to develop its initial product, although at a much slower pace than originally envisioned, primarily due to the lack of funding. Development is at a stage where the engineering team will need to be augmented in order to complete this first version of the FAST product. The Company has initiated discussions with 2 parties in respect to collaborative development or joint venture arrangements, but these are in preliminary stages, and there is no assurance that any such arrangements will be entered into.

The Company also announced that it has, subject to regulatory approval, appointed Richard Olson and Philip Beaudoin of Toronto and IR Smartt Inc. of Austin Texas as investor relations consultants. These parties will be paid a monthly fee and granted options in accordance with their agreements and the Company's stock option plan.

## **About QuikFlo**

QuikFlo is a medical software company developing innovative solutions for the analysis of medical images. Its primary focus is on improving outcomes for stroke patients, where existing time delays are solvable through more efficient triage based on rapid, accurate analysis of medical images.

## **Further Information**

For further information relating to the Company or this release please visit <a href="www.sedar.com">www.sedar.com</a>, <a href="www.sedar.com">www.guikflohealth.com</a>, or contact Vinny Jindal, President and CEO at 646.526.9628 or Investor Relations for the Company at 647.980.7541.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

## **Cautionary and Forward-Looking Statements**

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. Forward-looking statements are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although management of the Company believes that the expectations and assumptions on which such forward looking statements and information are based are currently reasonable, actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the suitability of the key members of ongoing management and the board of directors, the biomedical and technology sectors in general such as operational risks in development, research and regulatory delays or changes in plans with respect to research projects or capital expenditures; the uncertainty of the market; the uncertainty of estimates and projections relating to costs and expenses; health, safety and environmental risks; marketing and commercialization; loss of markets; competition; ability to access sufficient capital; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws, and government regulations, and other risks identified in the recent information circular available on www.sedar.com. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release.

No undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.